Price
CHART BY
Frequently asked questions
What is Citius Pharms's market capitalization?
The market capitalization of Citius Pharms is $16.49M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Citius Pharms?
Citius Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.111. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Citius Pharms's stock?
Currently, 1 analysts cover Citius Pharms's stock, with a consensus target price of $4.00. Analyst ratings provide insights into the stock's expected performance.
What is Citius Pharms's revenue over the trailing twelve months?
Over the trailing twelve months, Citius Pharms reported a revenue of $7.11M.
What is the EBITDA for Citius Pharms?
Citius Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$57.24M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Citius Pharms?
Citius Pharms has a free cash flow of -$34.87M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Citius Pharms have, and what sector and industry does it belong to?
Citius Pharms employs approximately 23 people. It operates in the Health Care sector, specifically within the Medical Specialties industry.
What is the free float of Citius Pharms's shares?
The free float of Citius Pharms is 26.96M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $16.49M
- EPS (TTM)
- -$2.111
- Free Float
- 26.96M
- Revenue (TTM)
- $7.11M
- EBITDA (TTM)
- -$57.24M
- Free Cashflow (TTM)
- -$34.87M
Pricing
- 52W span
- $0.47$2.18
Analyst Ratings
The price target is $4.00 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone, Leonard Mazur, Myron Holubiak on January 23, 2007 and is headquartered in Cranford, NJ.
- Employees
- 23
- Industries
- Medical Specialties
- Sector
- Health Care
Identifier
- Primary Ticker
- CTXR
Fundamentals & EOD data from FactSet